AAV vectors: is clinical success on the horizon?

Potential applications and impact of the adeno-associated virus (AAV) as a gene transfer vector have expanded rapidly in the last decade. Recent advances in the production of high-titer purified rAAV vector stocks have made the transition to human clinical trials a reality in the last moments of the millenium. Production improvements will be complemented in the coming years with understanding of and innovations in the targeting and packaging of rAAV, the design of transgene cassettes, and the host immune response to the vectors. These expected areas of progress are discussed, with special attention to clinical applications for which rAAV vectors may help close the gap towards successful gene therapy.

[1]  D. Grimm,et al.  Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. , 1999, Human gene therapy.

[2]  N. Young,et al.  Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. , 1996, Virology.

[3]  S. Kung,et al.  Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.

[4]  T. Flotte,et al.  Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus , 1998, The Lancet.

[5]  Linda Yang,et al.  Cloning and Characterization of Adeno-Associated Virus Type 5 , 1999, Journal of Virology.

[6]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Philip R. Johnson,et al.  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.

[8]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[9]  B. Byrne,et al.  High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap , 1999, Gene Therapy.

[10]  D. Bohl,et al.  Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. , 1998, Blood.

[11]  G. Deléage,et al.  Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 (Nature Medicine (1999) 5 (1052-1056)) , 1999 .

[12]  R. Samulski,et al.  Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. , 1999, Virology.

[13]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[14]  C. Walker,et al.  Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D , 1997, Journal of virology.

[15]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[16]  John E. Murphy,et al.  Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates , 1998, Gene Therapy.

[17]  James M. Wilson,et al.  Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.

[18]  S. Bidlingmaier,et al.  Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Yulong Zhang,et al.  Concatamerization of Adeno-Associated Virus Circular Genomes Occurs through Intermolecular Recombination , 1999, Journal of Virology.

[20]  James M. Wilson,et al.  Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.

[21]  M. Kay,et al.  Adeno-associated virus vectors and hematology. , 1999, Blood.

[22]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[23]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[24]  R. Samulski,et al.  Persistent expression of canine factor IX in hemophilia B canines , 1999, Gene Therapy.

[25]  E. Engleman,et al.  Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. , 1999, Clinical immunology.

[26]  T. Flotte,et al.  Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway , 1999, Journal of Virology.

[27]  D. Grimm,et al.  Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 , 1999, Gene Therapy.

[28]  Peter Belfer.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein , 1996 .

[29]  D. Russell,et al.  Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2 , 1998, Journal of Virology.

[30]  Keyun Qing,et al.  Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.

[31]  W. Hauswirth,et al.  Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa , 1998, Nature Medicine.

[32]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[33]  R. Samulski,et al.  Viral receptors and vector purification: New approaches for generating clinical-grade reagents , 1999, Nature Medicine.

[34]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[35]  T. Flotte,et al.  Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. , 1996, Gene therapy.

[36]  M. Kay,et al.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.

[37]  A. Bruce,et al.  Sustained expression of human factor VIII in mice using a parvovirus-based vector. , 2000, Blood.

[38]  B. Byrne,et al.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Parham,et al.  Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[40]  N. Munshi,et al.  In vitro packaging of an infectious recombinant adeno-associated virus 2 , 1997, Gene Therapy.

[41]  E. Wakeland,et al.  Gene transfer into hematopoietic progenitor cells mediated by an adeno-associated virus vector. , 1988, Virology.

[42]  S. Ponnazhagan,et al.  Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes , 1998, Journal of Virology.

[43]  Y. Kan,et al.  Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  N. Muzyczka,et al.  In Vitro Packaging of Adeno-Associated Virus DNA , 1998, Journal of Virology.

[45]  James M. Wilson,et al.  High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. , 1998, Human gene therapy.

[46]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[47]  R. Samulski,et al.  The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. , 2000, Human gene therapy.